Laboratory of Lymphocyte Signaling and Oncoproteome

ERANET-PLL approved

The project, “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia“, was granted funding within the European ERA-net TRANSCAN 2 initiative (Horizon 2020).

The project is a cooperation of five European research groups from Austria, France and Germany, coordinated by Dr. Marco Herling (University Hospital of Cologne). It focuses on the development of new tools to predict individual in vitro drug sensitivities and synergies in the rare entity of T-cell prolymphocytic leukemia and implementation of these into the clinics.

Overall, the project is funded with 1.5 million euros.

For more details visit:

https://www.transcanfp7.eu/index.php/abstract/eranet-pll.html

 

ERANET-PLL approved
Postet on July 5, 2019

More news

Inter­national Symposium on T cells and T-cell lymphomas

Inter­national Symposium on T cells and T-cell lymphomas

August 20, 2019

The symposium hosted by the CONTROL-T consortium will take place from 20-21.09.2019 in Essen.

Looking for a Post-Doc

July 19, 2019

in basic and translational biomedical sciences (particularly in cancer biology and immunology)